757247-09-9

Upstream product

• 757247-03-3 4-(tert-butyl-dimethyl-silanyloxy)-1-(2,2-dimethyl-3a,9b-dihydro-4H-chromeno[4,3-d]oxazol-1-yl)-butan-1-one 
• 757247-06-6 3-(2,2-dimethyl-3a,9b-dihydro-4H-chromeno[4,3-d]oxazole-1-carbonyl)-hex-5-enoic acid hydrazide 
• 757247-04-4 1-(2,2-dimethyl-3a,9b-dihydro-4H-chromeno[4,3-d]oxazol-1-yl)-2-(2-hydroxy-ethyl)-pent-4-en-1-one 
• 757247-02-2 4-(2,2-dimethyl-3a,9b-dihydro-4H-chromeno[4,3-d]oxazol-1-yl)-4-oxo-butyric acid methyl ester 
• 757247-01-1 N-((3S,4S)-3-Hydroxy-chroman-4-yl)-succinamic acid methyl ester 
• 138603-50-6 cis-4-amino-3-chromanol 

Relevant academic research and scientific papers

P1′ oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1

HIV-1 protease inhibitors bearing 1,3,4-oxadiazoles at the P1′ position are highly active against native and PI-resistant HIV-1. HIV-1 protease inhibitors (PI's) bearing 1,3,4-oxadiazoles at the P1′ position were prepared by a novel method involving the diastereoselective installation of a carboxylic acid and conversion to the P1′ heterocycle. The compounds are picomolar inhibitors of native HIV-1 protease, with most of the compounds maintaining excellent antiviral activity against a panel of PI-resistant strains.